CytoSeek is developing Artificial Membrane-Binding Protein (AMBP) technology to deliver cell therapies for cancer treatment. The company's AMBPs bind to cell types for precision membrane engineering to deliver new functionalities.

CytoSeek

CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies.

Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. 

CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health.

Future Planet Capital

UK Innovation & Science Seed Fund

Meltwind Advisory

SCVC

Parkwalk Advisors

We're #hiring a new Cell biologist to help develop our Artificial Membrane-Binding Protein technology! Apply today, get in touch, or share with anyone who may be interested!

25/03/2024—We've had a high volume of applicants, so we're pausing applications for now. Keep an eye out for future opportunities!

CYTO

UK:CYTOSEEK

CytoSeek

locale

market

industry

website

linkedin

investor of

Metrics